查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571491

DNA/RNA 銀行服務市場規模、佔有率、趨勢分析報告：按服務、檢體、應用、最終用途和細分市場進行預測，2024-2030 年

DNA & RNA Banking Services Market Size, Share & Trends Analysis Report By Service, By Specimen (Blood, Buccal Swabs & Hair Follicles, Others), By Application, By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

DNA/RNA 銀行服務市場的成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，預計 2030 年全球 DNA 和 RNA 銀行服務市場規模將達到 109.2 億美元，2024 年至 2030 年複合年成長率為 5.5%。

儲存 DNA 和 RNA 等人類生物資源的設施對於生物標記的發現至關重要，並為個人化醫療的擴展鋪平了道路。此外，透過引入先進和標準化的細胞分離技術，轉化和臨床研究的進步將減少工作時間。自動化解決方案和生物樣本庫全自動化的開拓可能會加速市場成長。

個人化醫療舉措的個人註冊人數的增加將推動 DNA 和 RNA 銀行服務的收益。 2019 年 7 月，Partners Healthcare（美國）在其精準醫療生物庫中招募了超過 10 萬人，該生物庫為布萊根婦女醫院（美國）和其他合作夥伴的臨床醫生和研究人員提供支援。這些努力有助於研究多種因素對疾病和健康的影響。

分銷網路不斷變得更加複雜，製藥公司面臨著與永續性工作、監管合規性以及競爭優先事項帶來的成本壓力相關的新挑戰。主要企業在不同地區投資低溫運輸倉儲和擴大分銷能力的努力提高了它們處理大量複雜低溫運輸生技藥品的能力。 EasyDNA、DNA Genotek、23andMe、GoodCell、ProteoGenex.、 美國 Biolab 等主要企業已採取多個策略聯盟來增加其在市場上的影響力。

DNA/RNA 銀行服務市場報告亮點

  • 按服務類型分類，2023年儲存服務佔銷售額的最大佔有率。自動化樣品儲存系統和自動化液體處理機的出現進一步推動了這一領域的發展，這些系統和自動化液體處理機可以管理大量樣品並減少處理、儲存和分發樣品所需的時間。
  • 從檢體類型來看，血液檢體由於採血速度快、時間短、污染風險最小以及血液檢體的可見度高，在2023年佔據市場主導地位。
  • 從應用來看，2023年藥物發現和臨床研究領域佔最大。生物銀行服務將為加速新療法的發現和未來研究更好地了解環境、遺傳和生活方式因素對人類健康、發病率和死亡率的影響提供資源。這些因素導致該細分市場的收益佔有率最大。
  • 根據最終用途，在政府機構和生物銀行努力擴大醫院和診斷中心用於 COVID-19 診斷的 DNA 和 RNA 樣本的推動下，醫院和診斷中心細分市場將在預測期內繼續成長。的成長。
  • 2023 年，北美地區的收益佔有率最大。積極加速市場成長的主要因素之一是美國「All of Us」生物庫等國家精準醫療措施的啟動。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 DNA/RNA 銀行服務市場的變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 產業分析-波特五力分析
    • 供應商的力量
    • 買家的力量
    • 另類威脅
    • 新進入的威脅
    • 競爭公司之間的敵對關係
  • PESTEL分析
    • 政局
    • 技術景觀
    • 經濟狀況

第4章 DNA/RNA銀行服務市場：服務評估與趨勢分析

  • 細分儀表板
  • DNA/RNA 銀行服務市場：2023 年和 2030 年服務變化分析
  • 交通服務
  • 加工服務
  • 倉儲服務
  • 品管服務
  • 資料儲存
  • 其他

第5章 DNA/RNA銀行服務市場：檢體估計與趨勢分析

  • 細分儀表板
  • DNA/RNA 銀行服務市場：檢體變異分析，2023 年和 2030 年
  • 血
  • 頰黏膜拭子和毛囊
  • 其他

第6章 DNA/RNA 銀行服務市場：使用量估計與趨勢分析

  • 細分儀表板
  • DNA/RNA 銀行服務市場：2023 年和 2030 年應用變化分析
  • 治療藥物
    • 2018年至2030年市場預測
  • 藥物發現與臨床研究
    • 2018年至2030年市場預測
  • 臨床診斷
    • 2018年至2030年市場預測
  • 其他用途
    • 2018年至2030年市場預測

第7章 DNA/RNA 銀行服務市場：最終用途估計與趨勢分析

  • 細分儀表板
  • DNA/RNA 銀行服務市場：最終用途變化分析，2023 年和 2030 年
  • 學術研究
  • 製藥和生物技術公司
  • 醫院和診斷中心
  • 其他

第8章 DNA/RNA銀行服務市場：區域估算與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場簡介
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
  • 公司簡介
    • EasyDNA
    • DNA Genotek Inc.
    • 23andMe, Inc.
    • GoodCell
    • ProteoGenex
    • US Biolab Corporation, Inc.
    • Infinity Biologix
    • Thermo Fisher Scientific, Inc.
    • deCODE genetics
    • AG Brooks Life Sciences
    • LGC Biosearch Technologies
    • PreventionGenetics
簡介目錄
Product Code: GVR-4-68039-325-9

DNA & RNA Banking Services Market Growth & Trends:

The global DNA & RNA banking services market size is expected to reach USD 10.92 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Biospecimens such as DNA and RNA are critical for biomarker discovery, thereby providing a path for the expansion of personalized medicine. Moreover, progress in translational and clinical research through an introduction of advanced, standardized cell isolation methodologies reduces hands-on-time. The development of automated solutions and the transformation of biobanks into fully automated biobanks potentially accelerate the growth of the market.

A rise in the enrollment of individuals for personalized medicine initiatives drives the revenue generation for DNA and RNA banking services. In July 2019, Partners HealthCare, U.S. enrolled more than 100,000 individuals in its precision medicine biobank that supported clinicians and researchers of the Brigham and Women's Hospital, U.S., and other partners. Such initiative assisted in examining the impact of several factors on disease and health.

The distribution network is continuously becoming complex, with pharmaceutical firms facing new challenges related to sustainability initiatives, regulatory adherence, and competing priorities cost pressures. The efforts undertaken by the key players to invest in the cold chain storage and expansion of distribution capability in various geographies have increased the capability to handle large quantities of complex cold chain biologics. Key companies such as EasyDNA, DNA Genotek, 23andMe, GoodCell, ProteoGenex., and US Biolab have adopted several strategic alliances to reinforce their market presence.

DNA & RNA Banking Services Market Report Highlights:

  • By service type, storage services accounted for the largest revenue share in 2023 owing to the presence of numerous key providers in the market space. The advent of automated sample storage systems and automated liquid handlers to manage large sample volume, and reduce the amount of time required to process, store, and distribute samples further drives the segment
  • Based on specimen type, the blood segment dominated the market in 2023 owing to fast and quick procedures of collecting blood, minimal risk of contamination, and visibility of blood samples
  • In terms of application, the drug discovery and clinical research segment held the largest share in 2023. Biobanking services are utilized to accelerate the discovery of new therapeutics and offer resources for future investigations to better understand the effects of environmental, genetic, and lifestyle factors on human health, morbidity, and mortality. This factor led to the maximum revenue share of the segment
  • On the basis of end use, the hospitals and diagnostic centers segment is projected to witness the fastest growth throughout the forecast period owing to the efforts undertaken by government bodies and biobanks to broaden the accessibility for DNA and RNA samples in the hospitals and diagnostic centers for COVID-19 diagnosis
  • North America accounted for the largest revenue share in 2023. One of the major factors positively accelerating market growth is the initiation of national precision-medicine initiatives, such as the "All of Us" biobank in the U.S.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. DNA & RNA Banking Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Industry Analysis - Porter's
    • 3.3.1. Supplier power
    • 3.3.2. Buyer power
    • 3.3.3. Substitution threat
    • 3.3.4. Threat of new entrant
    • 3.3.5. Competitive rivalry
  • 3.4. PESTEL Analysis
    • 3.4.1. Political landscape
    • 3.4.2. Technological landscape
    • 3.4.3. Economic landscape

Chapter 4. DNA & RNA Banking Services Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. DNA & RNA Banking Services Market: Service Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Transportation Service
    • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4. Processing Service
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Storage Service
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Quality Control Service
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Data Storage
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. DNA & RNA Banking Services Market: Specimen Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. DNA & RNA Banking Services Market: Specimen Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Blood
    • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4. Buccal Swabs & Hair Follicles
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. DNA & RNA Banking Services Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. DNA & RNA Banking Services Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Therapeutics
    • 6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Drug Discovery & Clinical Research
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Clinical Diagnostics
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Other Applications
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. DNA & RNA Banking Services Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. DNA & RNA Banking Services Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Academic Research
    • 7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Pharmaceutical & Biotechnology Companies
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Hospitals & Diagnostic Centers
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. DNA & RNA Banking Services Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
  • 9.4. Company Profiles
    • 9.4.1. EasyDNA
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Service benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. DNA Genotek Inc.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Service benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. 23andMe, Inc.
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Service benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. GoodCell
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Service benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. ProteoGenex
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Service benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. US Biolab Corporation, Inc.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Service benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Infinity Biologix
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Service benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Thermo Fisher Scientific, Inc.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Service benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. deCODE genetics
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Service benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. AG Brooks Life Sciences
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Service benchmarking
      • 9.4.10.4. Strategic initiatives
    • 9.4.11. LGC Biosearch Technologies
      • 9.4.11.1. Company overview
      • 9.4.11.2. Financial performance
      • 9.4.11.3. Service benchmarking
      • 9.4.11.4. Strategic initiatives
    • 9.4.12. PreventionGenetics
      • 9.4.12.1. Company overview
      • 9.4.12.2. Financial performance
      • 9.4.12.3. Service benchmarking
      • 9.4.12.4. Strategic initiatives